Biocon's Biosimilar YESINTEK Gets U.S. FDA Nod, Set to Treat Multiple Diseases - Dzambhala.io

Real-Time News FIRE NOW SIP Calculators

Easy-to-understand Financial Insights
that build Wealth.

Suit Of Products

Explore Dzambhala Pro

Biocon's Biosimilar YESINTEK Gets U.S. FDA Nod, Set to Treat Multiple Diseases

Dec. 1, 2024, 1:49 p.m.

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has received approval from the U.S. FDA for its biosimilar product YESINTEK.
YESINTEK is a biosimilar to Stelara (Ustekinumab), devel…

Unlock the Full Filing And Lot More

Access premium insights and stay ahead of the market with Dzambhala Pro.

BIOCON Regulatory